Genotype-Phenotype Correlations in 293 Russian Patients with Causal Fabry Disease Variants

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2023 Nov 25

PMID 38002959

Authors

Kirill Savostyanov

Alexander Pushkov

Ilya Zhanin

Natalya Mazanova

Alexander Pakhomov

Elena Trufanova

Alina Alexeeva

Dmitry Sladkov

Ludmila Kuzenkova

Aliy Asanov

Andrey Fisenko

Affiliations

Soon will be listed here.

Abstract

Background: Fabry disease (FD) is a rare hereditary multisystem disease caused by variants of the gene. Determination of gene variants and identification of genotype-phenotype correlations allow us to explain the features of FD associated with predominant damage of one or another system, both in the classical and atypical forms of FD, as well as in cases with late manifestation and involvement of one of the systems.

Methods: The study included 293 Russian patients with pathogenic variants of the gene, which were identified as a result of various selective screening programs. Screening was carried out for 48,428 high-risk patients using a two-step diagnostic algorithm, including the determination of the concentration of the biomarker lyso-Gb3 as a first-tier test. Screening of atypical FD among patients with HCM was carried out via high-throughput sequencing in another 2427 patients.

Results: 102 (0.20%) cases of FD were identified among unrelated patients as a result of the study of 50,855 patients. Molecular genetic testing allowed us to reveal the spectrum and frequencies of 104 different pathogenic variants of the gene in 293 examined patients from 133 families. The spectrum and frequencies of clinical manifestations in patients with FD, including 20 pediatric patients, were described. Correlations between the concentration of the lyso-Gb3 biomarker and the type of pathogenic variants of the gene have been established. Variants identified in patients with early stroke were described, and the association of certain variants with the development of stroke was established.

Conclusions: The results of a large-scale selective FD screening, as well as clinical and molecular genetic features, in a cohort of 293 Russian patients with FD are described.

Citing Articles

Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement.

Veldman B, Schoenmakers D, van Dussen L, Datema M, Langeveld M Int J Mol Sci. 2024; 25(17).

PMID: 39273698 PMC: 11396259. DOI: 10.3390/ijms25179752.

References

Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege A, Eladari D . X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2015; 89(1):44-54. DOI: 10.1111/cge.12613. View

Lukas J, Giese A, Markoff A, Grittner U, Kolodny E, Mascher H . Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet. 2013; 9(8):e1003632. PMC: 3731228. DOI: 10.1371/journal.pgen.1003632. View

Mills K, Johnson A, Winchester B . Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett. 2002; 515(1-3):171-6. DOI: 10.1016/s0014-5793(02)02491-2. View

Nance C, Klein C, Banikazemi M, Dikman S, Phelps R, McArthur J . Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol. 2006; 63(3):453-7. DOI: 10.1001/archneur.63.3.453. View

Meaney C, Blanch L, Morris C . A nonsense mutation (R220X) in the alpha-galactosidase A gene detected in a female carrier of Fabry disease. Hum Mol Genet. 1994; 3(6):1019-20. DOI: 10.1093/hmg/3.6.1019. View

Lukas J, Scalia S, Eichler S, Pockrandt A, Dehn N, Cozma C . Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease. Hum Mutat. 2015; 37(1):43-51. DOI: 10.1002/humu.22910. View

Citro V, Pena-Garcia J, den-Haan H, Perez-Sanchez H, Del Prete R, Liguori L . Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease. PLoS One. 2016; 11(10):e0165463. PMC: 5082870. DOI: 10.1371/journal.pone.0165463. View

Ellaway C . Paediatric Fabry disease. Transl Pediatr. 2016; 5(1):37-42. PMC: 4729035. DOI: 10.3978/j.issn.2224-4336.2015.12.02. View

Rombach S, Smid B, Bouwman M, Linthorst G, Dijkgraaf M, Hollak C . Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013; 8:47. PMC: 3626869. DOI: 10.1186/1750-1172-8-47. View

10.

Davies J, Winchester B, Malcolm S . Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet. 1993; 2(7):1051-3. DOI: 10.1093/hmg/2.7.1051. View

11.

Aerts J, Groener J, Kuiper S, Donker-Koopman W, Strijland A, Ottenhoff R . Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008; 105(8):2812-7. PMC: 2268542. DOI: 10.1073/pnas.0712309105. View

12.

Hoffmann B . Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009; 4:21. PMC: 2768700. DOI: 10.1186/1750-1172-4-21. View

13.

Frustaci A, Morgante E, Russo M, Scopelliti F, Grande C, Verardo R . Pathology and function of conduction tissue in Fabry disease cardiomyopathy. Circ Arrhythm Electrophysiol. 2015; 8(4):799-805. DOI: 10.1161/CIRCEP.114.002569. View

14.

Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A . Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene. PLoS One. 2013; 8(2):e55565. PMC: 3564750. DOI: 10.1371/journal.pone.0055565. View

15.

Savostyanov K, Pushkov A, Zhanin I, Mazanova N, Trufanov S, Pakhomov A . The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology. Orphanet J Rare Dis. 2022; 17(1):199. PMC: 9109305. DOI: 10.1186/s13023-022-02319-4. View

16.

Wang R, Lelis A, Mirocha J, Wilcox W . Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007; 9(1):34-45. DOI: 10.1097/gim.0b013e31802d8321. View

17.

Lavalle L, Thomas A, Beaton B, Ebrahim H, Reed M, Ramaswami U . Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. PLoS One. 2018; 13(4):e0193550. PMC: 5886405. DOI: 10.1371/journal.pone.0193550. View

18.

Bishop D, Calhoun D, Bernstein H, Hantzopoulos P, Quinn M, Desnick R . Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci U S A. 1986; 83(13):4859-63. PMC: 323842. DOI: 10.1073/pnas.83.13.4859. View

19.

Niemann M, Rolfs A, Stork S, Bijnens B, Breunig F, Beer M . Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014; 7(1):8-16. DOI: 10.1161/CIRCGENETICS.113.000249. View

20.

Moiseev S, Fomin V, Savostyanov K, Pushkov A, Moiseev A, Svistunov A . The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron. 2019; 141(4):249-255. PMC: 6492520. DOI: 10.1159/000495886. View